Liver metastases from prostate cancer, while uncommon, offer poor prognosis

[JimJimJimJim]

Jim Marshall (not a doctor) said ...

Five men who presented with liver metastases from prostate cancer responded poorly to treatment.

Four of them did not respond to hormone treatment, and response to docetaxel chemotherapy only lasted for 6 months on average.

Two of them tried Zytiga (abiraterone) but had no response.

... end Jim

Liver metastases in carcinoma of the prostate as an indicator of aggressive subtype refractory to hormonal therapy and duration of response to docetaxel monotherapy: A single institution experience.

This abstract is only available for 24 hours for members to get an email.

After 24 hours the abstract will only be available through the link to the ASCO site below.

 

Caution
This extract was published in association with the American Society of Clinical Oncology 2013 annual conference. Though the research behind it may have been excellent, your doctor cannot yet give much weight to it for a number of reasons, including:

• It is only an extract. The full paper may reveal information important for your treatment.
• The study has not yet had peer review - with doctors and researchers scrutinising the study closely for mistakes and limitations after it is published in a professional journal.
•  Your doctor may already be aware of a limitations of the findings because of their wider reading.

The link below is to a page or document that we do not control.
Parts of it may be wrong or misleading.
Check with your doctor if something interests you.
If it is temporarily or permanently unavailable, you may receive an error message.

Source URL: http://meetinglibrary.asco.org/content/113416-132